Drug intelligence / Profile preview

YL17231

Development stage: Phase 1
Lead developer: 280Bio
Modality: Small Molecules
Administration: Oral

Overview

YL17231 (also known as TEB-17231) is an orally bioavailable small molecule pan-RAS inhibitor being developed by 280Bio, a wholly owned subsidiary of Shanghai Yingli Pharmaceutical. The drug is designed to target the RAS signaling pathway by binding to the KRAS switch II pocket, a mechanism that allows it to inhibit various KRAS mutations. It is currently being investigated for the treatment of advanced solid tumors harboring KRAS mutations. YL17231 is in Phase 1 clinical development, where it is being evaluated for safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy in patients with KRAS-mutant advanced solid tumors, with the objective of establishing the recommended Phase 2 dose.

Other names: Pan-KRAS Inhibitor YL-17231

Targets

NRAS (Neuroblastoma RAS viral oncogene homolog)HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on YL17231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YL17231.

Explore the full profile